Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Allogene Therapeutics stock price, quote, forecast and news

ALLO
US0197701065
A2N6WN

Price

2.96
Today +/-
+0.27
Today %
+10.68 %
P

Allogene Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Allogene Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Allogene Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Allogene Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Allogene Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Allogene Therapeutics Stock Price History

DateAllogene Therapeutics Price
9/13/20242.96 undefined
9/12/20242.66 undefined
9/11/20242.91 undefined
9/10/20242.83 undefined
9/9/20242.48 undefined
9/6/20242.41 undefined
9/5/20242.51 undefined
9/4/20242.58 undefined
9/3/20242.51 undefined
8/30/20242.63 undefined
8/29/20242.66 undefined
8/28/20242.57 undefined
8/27/20242.68 undefined
8/26/20242.80 undefined
8/23/20242.61 undefined
8/22/20242.59 undefined
8/21/20242.74 undefined
8/20/20242.64 undefined
8/19/20242.65 undefined

Allogene Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Allogene Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Allogene Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Allogene Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Allogene Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Allogene Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Allogene Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Allogene Therapeutics’s growth potential.

Allogene Therapeutics Revenue, EBIT and net profit per share

DateAllogene Therapeutics RevenueAllogene Therapeutics EBITAllogene Therapeutics Net Income
2030e2.3 B undefined978.45 M undefined1.12 B undefined
2029e585.12 M undefined683.27 M undefined165.94 M undefined
2028e309.04 M undefined-171.34 M undefined-99.33 M undefined
2027e145.03 M undefined-283.8 M undefined-239.7 M undefined
2026e21.98 M undefined-351.81 M undefined-319.84 M undefined
2025e4.2 M undefined-312.53 M undefined-312.86 M undefined
2024e65,667.6 undefined-290.04 M undefined-322.65 M undefined
202395,000 undefined-314.49 M undefined-327.27 M undefined
2022240,000 undefined-335.45 M undefined-332.63 M undefined
202138.49 M undefined-255.79 M undefined-257.01 M undefined
20200 undefined-258.24 M undefined-250.22 M undefined
20190 undefined-197.51 M undefined-184.59 M undefined
20180 undefined-182.74 M undefined-211.51 M undefined
20170 undefined0 undefined0 undefined

Allogene Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00000.0400000.020.150.310.592.3
---------425.00590.48113.1089.32293.33
--------------
00000000000000
0-182-197-258-255-335-314-290-312-351-283-171683978
-----671.05----7,800.00-1,671.43-195.17-55.34116.7542.50
0-0.21-0.18-0.25-0.26-0.33-0.33-0.32-0.31-0.32-0.24-0.10.171.12
---12.8035.872.8029.18-1.51-1.53-3.112.24-25.08-58.58-266.67580.00
115.23121.48101.06120.37135.82143.15156.930000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Allogene Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Allogene Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
0459.4530.5827.9457.3517.3448.7
0002.81.91.81.7
0000000
0000000
08.611.614.412.19.78.72
0468542.1845.1471.3528.8459.12
041.6100.9160.1181196.4163.18
026263.2207.9370.2723.65
0000000
08002000000
0000000
01.58.914.616.119.916.9
0305.9173.2382.6567.3288.3183.72
00.770.721.231.040.820.64
             
0100100100100100169
00.911.021.731.821.912.08
0-211.5-396.1-646.3-903.3-1,236-1,562.23
00.31.10.3-2.6-9.9-0.96
0000000
00.70.631.080.920.670.51
012.39.310.410.313.95.9
017.123.844.937.539.731.1
000390.40.90.09
0000000
0000000
029.433.194.348.254.537.08
0000000
0000000
041.255.753.974.196.793.53
041.255.753.974.196.793.53
070.688.8148.2122.3151.2130.6
00.770.721.231.040.820.64
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Allogene Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Allogene Therapeutics's financial health and stability.

Assets

Allogene Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Allogene Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Allogene Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Allogene Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
0-211-184-250-257-332-327
0157101414
0000000
011-753-323-15
017195138174177156
0000000
0000000
0-44-137-115-184-220-237
0-3-50-65-21-5-1
0-632164-505163106163
0-629214-439185111164
0000000
011600000
06545863311295
07715863311295
-------
0000000
0938513-9-11121
0-47.88-188.14-181.05-206.26-225.71-239.25
0000000

Allogene Therapeutics stock margins

The Allogene Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Allogene Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Allogene Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Allogene Therapeutics's sales revenue. A higher gross margin percentage indicates that the Allogene Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Allogene Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Allogene Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Allogene Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Allogene Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Allogene Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Allogene Therapeutics Margin History

Allogene Therapeutics Gross marginAllogene Therapeutics Profit marginAllogene Therapeutics EBIT marginAllogene Therapeutics Profit margin
2030e0 %42.52 %48.78 %
2029e0 %116.77 %28.36 %
2028e0 %-55.44 %-32.14 %
2027e0 %-195.68 %-165.27 %
2026e0 %-1,600.43 %-1,455.02 %
2025e0 %-7,444.77 %-7,452.68 %
2024e0 %-441,678.74 %-491,340.28 %
20230 %-331,044.21 %-344,489.5 %
20220 %-139,770.84 %-138,595.84 %
20210 %-664.56 %-667.73 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Allogene Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Allogene Therapeutics earnings per share therefore indicates how much revenue Allogene Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Allogene Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Allogene Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Allogene Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Allogene Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Allogene Therapeutics Revenue, EBIT and net profit per share

DateAllogene Therapeutics Sales per ShareAllogene Therapeutics EBIT per shareAllogene Therapeutics Earnings per Share
2030e11 undefined0 undefined5.37 undefined
2029e2.8 undefined0 undefined0.79 undefined
2028e1.48 undefined0 undefined-0.48 undefined
2027e0.69 undefined0 undefined-1.15 undefined
2026e0.11 undefined0 undefined-1.53 undefined
2025e0.02 undefined0 undefined-1.5 undefined
2024e0 undefined0 undefined-1.54 undefined
20230 undefined-2 undefined-2.09 undefined
20220 undefined-2.34 undefined-2.32 undefined
20210.28 undefined-1.88 undefined-1.89 undefined
20200 undefined-2.15 undefined-2.08 undefined
20190 undefined-1.95 undefined-1.83 undefined
20180 undefined-1.5 undefined-1.74 undefined
20170 undefined0 undefined0 undefined

Allogene Therapeutics business model

Allogene Therapeutics Inc. is an innovative biotechnology company specializing in the discovery and development of therapeutic approaches for cancer patients. The company, based in South San Francisco, California, was founded in 2018 and focuses on the manufacture of allogeneic CD19 CAR-T cell therapies. Allogene Therapeutics is one of the most popular companies on Eulerpool.com.

Allogene Therapeutics SWOT Analysis

Strengths

  • Allogene Therapeutics Inc is at the forefront of the emerging field of allogeneic cell therapy, which has the potential to revolutionize the treatment of various diseases.
  • The company has a strong portfolio of proprietary technology and intellectual property related to allogeneic cell therapy, giving them a competitive advantage in the market.
  • Allogene Therapeutics Inc has established strategic partnerships with leading research institutions and biopharmaceutical companies, enabling access to cutting-edge research and development.
  • The company's management team consists of experienced professionals with a track record of success in the biotechnology industry.

Weaknesses

  • Allogene Therapeutics Inc heavily relies on the success of its research and development efforts, which can be unpredictable and time-consuming.
  • The company is still in the early stages of clinical trials, meaning there is inherent risk and uncertainty associated with the outcome of these trials.
  • As a relatively small biotechnology company, Allogene Therapeutics Inc may lack the financial resources and infrastructure of larger competitors.
  • The success of allogeneic cell therapy relies on regulatory approval and acceptance by healthcare professionals, which can be challenging and time-consuming to obtain.

Opportunities

  • The global cell therapy market is expected to witness significant growth in the coming years, providing ample opportunities for Allogene Therapeutics Inc to expand its market share.
  • Advances in gene editing and cellular engineering technologies present opportunities for further enhancing the efficacy and safety of allogeneic cell therapies.
  • Emerging markets, such as Asia, offer untapped potential for the adoption of allogeneic cell therapy, providing an opportunity for geographic expansion.
  • Collaborations and partnerships with biopharmaceutical companies can provide access to additional resources, expertise, and distribution channels.

Threats

  • The field of allogeneic cell therapy is highly competitive, with the presence of established companies and intense research and development activities.
  • There is a risk of unforeseen adverse events or long-term safety concerns related to allogeneic cell therapy that could impact the reputation and acceptance of the technology.
  • Regulatory challenges and requirements for approval can place significant time and financial burdens on Allogene Therapeutics Inc, potentially delaying market entry.
  • Economic and political factors, as well as changes in healthcare policies, can impact the reimbursement landscape for allogeneic cell therapies.

Allogene Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Allogene Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Allogene Therapeutics shares outstanding

The number of shares was Allogene Therapeutics in 2023 — This indicates how many shares 156.932 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Allogene Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Allogene Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Allogene Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Allogene Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Allogene Therapeutics.

Allogene Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.35 -0.35  (1.21 %)2024 Q2
3/31/2024-0.42 -0.38  (8.98 %)2024 Q1
12/31/2023-0.46 -0.43  (6.13 %)2023 Q4
9/30/2023-0.53 -0.37  (30.18 %)2023 Q3
6/30/2023-0.6 -0.53  (11.77 %)2023 Q2
3/31/2023-0.63 -0.68  (-8.02 %)2023 Q1
12/31/2022-0.71 -0.66  (7.43 %)2022 Q4
9/30/2022-0.66 -0.58  (11.76 %)2022 Q3
6/30/2022-0.62 -0.52  (16.43 %)2022 Q2
3/31/2022-0.59 -0.56  (4.62 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Allogene Therapeutics stock

Eulerpool World ESG Rating (EESG©)

59/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

22

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees52
Share of Asian management—
Percentage of Hispanic/Latino employees7
Hispano/Latino Management share—
Percentage of Black employees1
Black Management Share—
Percentage of white employees33
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Allogene Therapeutics list of shareholders

%
Name
Stocks
Change
Date
8.95046 % TPG Capital, L.P.18,716,306012/31/2023
4.31231 % The Vanguard Group, Inc.9,017,465-1,556,97912/31/2023
4.05441 % BlackRock Institutional Trust Company, N.A.8,478,1741,271,90412/31/2023
2.61213 % Belldegrun (Arie S)5,462,224211,9731/25/2024
2.58635 % Chang (David D M.D., Ph.D.)5,408,316-53,3933/14/2024
2.52589 % PRIMECAP Management Company5,281,886-2,50012/31/2023
12.07092 % Fidelity Management & Research Company LLC25,241,49997,56812/31/2023
10.53610 % Pfizer Inc22,032,04008/2/2023
1.93832 % Citadel Advisors LLC4,053,226-62,40412/31/2023
1.85414 % JP Morgan Asset Management3,877,193-25,20012/31/2023
1
2
3
4
5
...
10

Allogene Therapeutics Executives and Management Board

Dr. David Chang63
Allogene Therapeutics President, Chief Executive Officer, Co-Founder, Director (since 2018)
Compensation 14.8 M
Dr. Arie Belldegrun73
Allogene Therapeutics Executive Chairman of the Board (since 2017)
Compensation 9.81 M
Mr. Joshua Kazam46
Allogene Therapeutics Director (since 2017)
Compensation 1.14 M
Dr. Stephen Mayo61
Allogene Therapeutics Independent Director
Compensation 873,760
Dr. Franz Humer76
Allogene Therapeutics Independent Director
Compensation 584,992
1
2
3
4

Most common questions regarding Allogene Therapeutics

What values and corporate philosophy does Allogene Therapeutics represent?

Allogene Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize the field of cancer treatment by harnessing the potential of allogeneic cell therapies. By leveraging cutting-edge technologies and strategic partnerships, Allogene Therapeutics Inc strives to deliver transformative therapies to patients worldwide. With a focus on improving outcomes and addressing unmet medical needs, the company is committed to advancing breakthrough therapies for various types of cancer. Allogene Therapeutics Inc's dedication to scientific excellence and commitment to patients underscores its mission to bring novel cell therapies to market and improve the lives of those affected by cancer.

In which countries and regions is Allogene Therapeutics primarily present?

Allogene Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Allogene Therapeutics achieved?

Allogene Therapeutics Inc has achieved significant milestones since its establishment. Notably, the company successfully completed its initial public offering in October 2018, raising a substantial amount of capital to support its research and development efforts. The following year, Allogene Therapeutics initiated its first clinical trial evaluating its proprietary allogeneic CAR-T therapy, ALLO-501, for the treatment of relapsed/refractory non-Hodgkin lymphoma. Moreover, in 2020, the company received the prestigious Breakthrough Therapy Designation from the U.S. FDA for ALLO-501, recognizing its potential to address unmet medical needs. These achievements highlight Allogene Therapeutics' commitment to advancing innovative cellular therapies to transform the lives of patients with cancer.

What is the history and background of the company Allogene Therapeutics?

Allogene Therapeutics Inc. is a biotechnology company specializing in the development of innovative cell therapies for cancer treatment. Founded in 2018, the company has quickly gained recognition for its groundbreaking approach to utilizing allogeneic, or off-the-shelf, CAR T cell therapy. With a mission to revolutionize cancer treatment, Allogene Therapeutics has established strategic partnerships and collaborations to accelerate the development and commercialization of their therapies. They aim to provide potentially curative treatments for patients battling various types of cancer. Allogene Therapeutics Inc. is committed to advancing the field of cellular immunotherapy in its quest to improve patient outcomes and transform cancer care.

Who are the main competitors of Allogene Therapeutics in the market?

The main competitors of Allogene Therapeutics Inc in the market include companies like Novartis AG, Pfizer Inc, and Cellectis SA.

In which industries is Allogene Therapeutics primarily active?

Allogene Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Allogene Therapeutics?

Allogene Therapeutics Inc is a biotechnology company specializing in the development of allogeneic T cell therapies for cancer treatment. Their business model revolves around the advancement and commercialization of groundbreaking immunotherapies. By harnessing the power of genetically engineered T cells from healthy donors, Allogene aims to provide readily available and potentially more effective therapeutic options for patients. The company collaborates with academic institutions, pharmaceutical companies, and pioneers in the field to accelerate the development of innovative treatments. Allogene Therapeutics Inc's business model focuses on transforming cancer care through the utilization of allogeneic cell therapies, aiming to improve patient outcomes and contribute to the advancement of oncology research.

What is the P/E ratio of Allogene Therapeutics 2024?

The Allogene Therapeutics P/E ratio is -1.44.

What is the P/S ratio of Allogene Therapeutics 2024?

The Allogene Therapeutics P/S ratio is 7,073.78.

What is the AlleAktien quality score of Allogene Therapeutics?

The AlleAktien quality score for Allogene Therapeutics is 2/10.

What is the revenue of Allogene Therapeutics 2024?

The expected Allogene Therapeutics revenue is 65,667.6 USD.

How high is the profit of Allogene Therapeutics 2024?

The expected Allogene Therapeutics profit is -322.65 M USD.

What is the business model of Allogene Therapeutics

Allogene Therapeutics Inc is an innovative biopharmaceutical company specializing in the development of allogeneic CAR-T therapies for the treatment of severe cancers. The company focuses on developing gene therapies that can specifically target and destroy cancer cells due to their high effectiveness and specific mode of action. The company has a unique business model that enables the development and commercialization of cancer treatments in innovative ways. By using allogeneic cells from other donors instead of autologous cells from the patient, Allogene Therapeutics can offer faster and more cost-effective treatments. The treatment can be completed within a few weeks. The company aims to develop and market a wide range of allogeneic therapies for various types of cancer. They are working on developing gene therapies that selectively activate the immune system to fight cancer cells. One of their key drug candidates is ALLO-501, an allogeneic CAR-T cell therapy program used in combination with lymphodepletion in patients with non-Hodgkin lymphoma (NHL). The company also has a wide range of product candidates, including ALLO-715, used for the treatment of patients with severe multiple myeloma, and ALLO-647, an immunosuppressive molecule designed to prevent potential immune reactions against allogeneic cell therapies. Through a partnership with Servier, Allogene Therapeutics has also gained a strategic position in Europe. This partnership aims to expand access to allogeneic CAR-T cells to meet the needs of patients with difficult-to-treat blood cancers. Recently, the company completed a funding round of over $700 million to further advance its clinical studies and development pipeline. The company plans to use these funds to conduct additional clinical trials and bring their product candidates to market. As a leading provider of allogeneic CAR-T therapies, Allogene Therapeutics is committed to revolutionizing cancer treatment. Their innovative business model and groundbreaking gene therapies have the potential to improve the lives of cancer patients worldwide and successfully fight against cancer.

What is the Allogene Therapeutics dividend?

Allogene Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Allogene Therapeutics pay dividends?

The dividend cannot currently be calculated for Allogene Therapeutics or the company does not pay out a dividend.

What is the Allogene Therapeutics ISIN?

The ISIN of Allogene Therapeutics is US0197701065.

What is the Allogene Therapeutics WKN?

The WKN of Allogene Therapeutics is A2N6WN.

What is the Allogene Therapeutics ticker?

The ticker of Allogene Therapeutics is ALLO.

How much dividend does Allogene Therapeutics pay?

Over the past 12 months, Allogene Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Allogene Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Allogene Therapeutics?

The current dividend yield of Allogene Therapeutics is .

When does Allogene Therapeutics pay dividends?

Allogene Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Allogene Therapeutics?

Allogene Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Allogene Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Allogene Therapeutics located?

Allogene Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Allogene Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Allogene Therapeutics from 9/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did Allogene Therapeutics pay the last dividend?

The last dividend was paid out on 9/16/2024.

What was the dividend of Allogene Therapeutics in the year 2023?

In the year 2023, Allogene Therapeutics distributed 0 USD as dividends.

In which currency does Allogene Therapeutics pay out the dividend?

The dividends of Allogene Therapeutics are distributed in USD.

All fundamentals about Allogene Therapeutics

Our stock analysis for Allogene Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Allogene Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.